Qulipta indication expanded to include prevention of chronic migraine

The FDA has expanded the approval of the oral CGRP receptor antagonist atogepant (Qulipta) to include the preventive treatment of chronic migraine. Previously, the drug had been indicated only for the prevention of episodic migraine. The recommended dose for chronic migraine is 60 mg once daily.